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ZUSAMMENFASSUNG 
Molecular and immunohistochemical characterisation of 
matched primary and metastatic Ewing sarcomas
Dennis Wentker
Die Diagnostik von Ewing-Sarkomen (ES) basiert auf  molekularpathologischen und 
immunhistochemischen Analyseverfahren. In einer früheren Arbeit wurde ein Patient 
mit zwei separaten ES beschrieben, in denen unterschiedliche EWSR1-
Translokationen nachgewiesen wurden. Zur Differenzierung, ob es sich bei manchen 
vermeintlichen Metastasen um eigenständige Tumoren handelt, wurden Primärtumoren 
und Metastasen auf die ES-spezifischen EWSR1-Translokationen untersucht. Zudem 
wurden immunhistochemische Färbungen durchgeführt, um Unterschiede in der 
Markerexpression von Primärtumoren und korrespondierenden Metastasen zu 
evaluieren. 
Formalin-fixiertes, Paraffin-eingebettetes (FFPE) bzw. gefrorenes Material von 39 
Primärtumoren und den korrespondierenden Metastasen wurde auf ES-spezifische 
Fusionstranskripte molekularpathologisch untersucht. Des Weiteren wurden tissue 
microarrays erstellt, um die immunhistochemischen Expressionsprofile von 
Primärtumoren und Metastasen miteinander zu vergleichen. Die Primärtumoren und 
die korrespondierenden Metastasen wiesen alle den jeweils identischen 
Translokationstyp auf. AK16-, CD99- und FLI-1-Antikörper zeigten eine hohe 
Sensitivität sowie eine gute Konkordanz in der Markerexpression zwischen 
Primärtumoren und Metastasen.
AK16-, CD99- und FLI-1-Antikörper können zur Diagnose von ES-Metastasen 
verwendet werden, falls der Nachweis eines ES-spezifischen Fusionstranskriptes an 
FFPE-Tumormaterial nicht gelingt. Primärtumoren und Metastasen weisen in der Regel 
identische Fusionstranskripte auf, und das Vorhandensein zweier separater ES mit 
divergierenden Translokationstypen bei einem Patienten stellt ein seltenes Ereignis 
dar.
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1 Introduction
Ewing sarcoma (ES) is  a malignant small round-cell tumor of the bone and was 
described for the first time by James Ewing in 1921. [10] It is the second most 
common malignant bone tumor in childhood and young adults after 
osteosarcoma. The incidence of ES in children and adolescents is 
approximately 3 per million annually. The progress in local therapy and systemic 
chemotherapy in the last decades improved the 5-year survival from 44% to 
68% for patients with localised disease. [9, 14]
About 25% of the patients have detectable metastases at diagnosis, which is a 
major adverse prognostic factor. The most common metastatic sites are the 
skeletal system, the lungs and the bone marrow. Patients with pulmonary 
metastases have a better prognosis  than patients with bone or bone marrow 
metastases at primary diagnosis. The 5-year survival for patients presenting 
with metastatic disease at primary diagnosis  increased from 16% to 39% in the 
last decades. [1, 9] Local relapse within 2 years after the primary diagnosis  is 
another prognosis-deteriorating factor. However, the local relapse rate could be 
decreased to 15% for axial tumors and 4% for all other sites since 1986. [5]
In nearly all cases of ES the EWSR1 gene is rearranged to one ETS family 
transcription factor. The most common fusion partner of EWSR1 is FLI-1 
[t(11;22)(q24;q12)]. About 85% of ES tumors carry this translocation and the 
EWSR1/FLI-1 fusion protein functions as a aberrant transcription factor which 
causes the dysregulated expression of several genes. [18] In 10-15% of cases 
the ETS DNA-binding-domain is  contributed from ERG [t(21;22)(q22;q12)] and 
in rare cases  from ETV-1 [t(7;22)(q22;q12)], E1AF [t(17;22)(q12;q12)], or 
1
FEV [t(2;22)(q33;q12)]. [6] For EWSR1/FLI-1 and EWSR1/ERG translocations, 
variants with breakpoints in different introns of EWSR1, FLI-1 and ERG can be 
found. In the most common translocations EWSR1 exon 7 is  juxtaposed to exon 
6 (type 1, 55.5%) or exon 5 (type 2, 18.5%) of FLI-1 or exons 6 (3.5%), 7 (2.0%) 
or 9 (2.0%) of ERG. EWRS1 exon 10 and FLI-1 exon 6 combination (type 3) 
account for another 11% of translocations. [15] 
Due to the specificity of EWSR1 translocations for ES and the presence in 
nearly all ES cases, the detection of these rearrangements is an important 
support in the diagnosis of ES. Here, the use of reverse-transcription-
polymerase chain reaction (RT-PCR) has become the most preferred method. 
Another important diagnostic tool is the immunohistochemical analysis of ES 
tumor samples. Although no immunohistochemical stain can exclusively be 
used for diagnosis of ES, anti-CD99 and -FLI-1 antibodies are useful markers. 
[6, 12, 16, 20, 24]
We once presented a patient, in whom two separate ES with different EWSR1 
translocations were observed and speculated that EWSR1 translocations might 
not be the first step in evolution of these ES, but could be preceded by so far 
undetected genomic aberrations. [2]
To further investigate whether the appearance of separate ES with differing 
EWRS1 translocations are frequent events in ES patients, we analysed 
samples taken from another 39 ES patients, who either presented with 
metastases or multifocal disease at diagnosis (n = 5) or developed metastases/
relapses during the period under review (n = 35), for t(11;22) or t(21;22) 
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translocations by RT-PCR. In addition, we performed immunohistochemistry on 
suitable samples to analyse whether corresponding primary and metastatic 
tumor samples differ in marker expression. 
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2 Materials & Methods
2.1 Case selection
The files of the Department of Pathology of the University Hospital Muenster, 
Germany, were searched for ES patients presenting with metastatic, multifocal 
and/or local relapsing disease and of whom specimens of primary tumors and 
metastases were available for molecular and immunohistochemical analysis. In 
addition to the then described patient (no. 26 of Table 1 [2]), 39 patients were 
identified to fulfil these criteria. Ninety-one tumor samples of these 39 patients 
were available for analysis by RT-PCR (20 fresh frozen (FT = frozen tissue) and 
71 formalin-fixed, paraffin-embedded (FFPE) specimens). Fifty-four FFPE 
samples taken from 34 of all 40 patients were suitable for immunohistochemical 
research (patient no. 26 included). In 2 cases, specimens of the first metastasis 
but not of the primary tumor were available. Hence, further material of 
elsewhere localised and temporally differing metastases  was analysed. The 
patients were either treated according to the EURO-E.W.I.N.G. 99 (n = 20), the 
EICESS 92 (n = 15) or the CESS 86 protocol (n = 1). [21] 
Four patients were consult patients and not treated according to these 
protocols. Table 1 gives an overview of all patients and their courses of disease.
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Patient
No.
Primary 
tumor site
Age at 
diagnosis 
[yrs.]
EFS 
[mths.] 1. metastasis
EFS
[mths.] 
2. 
metastasis
Period 
under  
review 
[mths.]
Outcome
1 humerus 29 9 multifocal (lung ) 15 pelvis 26 D
2 spine 16 47 spine (LR) 23 pleura 97 A
3 pelvis 10 5 lung 24 A
4 pelvis 16 43 lung 75 A
5 femur 17 0 lung 39 A
6 pelvis 35 45 lung N/A
7 femur 16 24 lung 65 D
8 tibia 12 11 lung 17 A
9 tibia 15 97 lung 7 pleura 119 D
10 pelvis 18 50 bronchus 10 lung 62 D
11 humerus 39 96 pleura 9 lung 112 A
12 tibia 19 59 multifocal (lung) 83 A
13 rib 16 20 pericardium 41 D
14 pelvis 41 11 lung 23 D
15 pelvis 21 6 lung 44 A
16 fibula 24 6 multifocal (lung / pericardium) 25 A
17 spine 14 67 lung 98 A
18 vulva 13 4 multifocal (groin / perianal) N/A
19 tibia 17 0 pelvis 14 A
20 femur 9 64 skull 4 ribs 203 A
21 scapula 24 6 scapula (LR) 29 D
22 fibula 15 20 skull 31 D
23 neck 42 11 neck N/A
24 femur 35 27 mamma 76 A
25 pelvis 18 13 pelvis N/A
26 Spine [2] 14 58 humerus 101 A
27 hallux 14 1 tibia 15 D
28 fermur 10 13 pelvis 23 D
29 pelvis 11 12 pelvis (LR) 12 D
30 tibia 13 48 pelvis 62 D
31 pelvis 17 19 multifocal (pleura) 9 Pleura 37 D
32 pelvis 13 0 humerus 118 A
33 spine 9 0 femur 39 spine 52 A
34 left femur 12 13 right femur 22 D
35 pelvis 20 14 lung 19 D
36 spine 20 19 multifocal (spine) N/A
37 right tibia 16 38 multifocal (heart / soft tissue mediastinal) 40 D
38 spine 10 14 mandible 25 D
39 femur 17 19 humerus 8 rib 40 D
40 pelvis 10 19 soft tissue (skull temporal) 32 D 
Table 1: Course of disease. EFS = event free survival; outcome: A = alive, 
D = dead; LR = local relapse; N/A = not available; yrs. = years; mths. = months.
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2.2 RNA extraction
Three to five 10 µm thick FFPE tissue sections were deparaffinized two times 
with 500 µl xylene (incubation at 36°C for 15 min), washed twice with 100% 
ethanol, dried for 2 min using a vacuum concentrator (Bachofer, Reutlingen, 
Germany), and lysed for 16-24 h in 230 µl of RNA digestion-buffer (20 mM Tris 
pH 7,5, 20 mM EDTA, 1% SDS in DEPC treated water) with 20 µl of 2% 
proteinase K solution (Merck, Germany) at 56°C. If lysis  was incomplete, 
another 20 µl of the proteinase K solution were added and incubated for 2-3 h 
until complete disappearance of tissue fragments. In order to extract RNA from 
the lysate, 2 ml of Trifast® (PeqLab, Erlangen, Germany, contains guanidine 
isothiocyanate and phenol) were added and further steps were done according 
to the manufacturer’s protocol. The precipitated RNA was resuspended in 90 µl 
of DEPC treated water, DNA digested by adding 10 µl of RNase-free DNase 
(final concentration: 0.1 U/µl, Eurogentec Germany, Cologne, Germany) 
supplemented by 0,5 µl of RNAguard™ (final concentration: 0,162 U/µl, GE 
Healthcare, Munich, Germany) and again Trifast® extracted. 
RNA concentration and purity was measured at 280 nm in a photometer. The 
RNA was afterwards stored at -80°C.
2.3 Nested PCR
Reverse transcription and first round PCRs were performed in one tube using 
the Titan One tube RT-PCR System (Roche, Mannheim, Germany) with 1 µg 
RNA (in a final reaction volume of 25 µl). Reverse transcription was carried out 
for 30 min at 50°C followed by first denaturation and inactivation of the Reverse 
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Transcriptase at 94°C for 2 min. Afterwards, amplification was performed by 35 
cycles of 30 sec 94°C denaturation, 30 sec annealing at optimum temperature 
(Table 2), 60 sec 68°C polymerisation, with extension of the polymerisation-time 
in the last 25 cycles  by additional 5 seconds for each cycle. A final step of 7 min 
at 68°C was added. To evaluate whether the extracted RNA was appropriate for 
further analysis, RT-PCR was first performed for a glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) fragment and products  were analysed by gel 
electrophoresis on 12% polyacrylamide gels. Only samples in which a GAPDH 
fragment could be amplified were further analysed. For detection of EWSR1-
translocation, first round PCR was followed by nested PCR using 2 µl of first 
round PCR as template (30 sec 94°C denaturation, 30 sec annealing at 
optimum temperature, 45 sec 72°C polymerisation). First, all samples were 
tested for fusion products like EWSR1 7/FLI-1 6 or EWSR1 7/FLI-1 5 (primer 
pair A) and for EWSR1/ERG fusion products (primer pair B). In case of negative 
results, primers for longer transcripts (like EWSR1 10/FLI-1 6 or EWSR1 10/
FLI-1 5) were used (primer pair C). To exclude false negative results caused by 
too much amplification-product, samples were additionally used in a 1:50 
dilution within the nested PCR reaction. Each trial was accompanied by positive 
and negative controls. PCR reactions were performed on a MJ Research PTC 
200 Thermal Cycler and products were subsequently analysed by gel 
electrophoresis. After purification using the Qiagen PCR purification Kit, PCR 
products were directly sequenced using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) and the same primers as used in the 
nested PCR. Sequencing-reaction conditions were: 4 min at 96°C followed by 
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35 cycles of 30 sec 96°C, 20 sec 50°C and 2 min 60°C. To remove 
unincorporated dyes from the sequencing reaction, the Qiagen DyeEx 2.0 Spin 
Kit was used. Capillary electrophoresis was performed on a 3730 capillar 
sequencer (Applied Biosystems) and the results were evaluated using the 
Seqscanner programme of Applied Biosystems. The exact exon breakpoints 
were determined by comparing the sequences with the NCBI database using 
the Blast 2 software 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi?0). 
In one case (no. 14 of Table 1), 2 bands were seen after electrophoresis on the 
polyacrylamide gel. This sample was unsewed on a 1% agarose gel and the 
bands were separately cut out of the gel and extracted using the Qiaquick gel 
extraction kit (Qiagen) and afterwards analysed as described above. 
PCR
Primer-
pairs
Sequence [5’ -> 3’]
Annealing 
temperature
First round 
PCR
A: EWS TCCTACAGCCAAGCTCCAAGTC 65 °C
A: FLI-1 GAATTGCCACAGCTGGATCTGC 65 °C
B: EWS TCCTACAGCCAAGCTCCAAGTC 65 °C
B: ERG GAGTTGGAGCTGTCCGACAGG 65 °C
C: EWS GAGAGCGAGGTGGCTTCA 55 °C
C: FLI-1 GGATCTGATACGGATCTGGC 55 °C
Nested PCR
A: EWS CAGAGCAGCAGCTACGGGCA 60 °C
A: FLI-1 AGGGTTGGCTAGGCGACTGCT 60 °C
B: EWS CAGAGCAGCAGCTACGGGCA 60 °C
B: ERG AGSAGCTCCAGGAGGAATTGCCA 60 °C
C: EWS GTGGCTTCAATAAGCCTGGT 55 °C
C: FLI-1 GGCCGTTGCTCTGTATTCTT 55 °C
GAPDH-
PCR
GAPDH GCATTGCTGATGATCTTGAGGCT 63 °C
GAPDH CACCCATGGCAAATTCCATGGC 63 °C
Table 2: Primers used in first round and nested PCR. 
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2.4 Fluorescence in situ hybridization (FISH)
Three-µm sections were cut from FFPE samples and processed for FISH using 
the EWSR1 (22q12) dual color, break apart rearrangement probe (Vysis, Abbott 
diagnostics, Wiesbaden, Germany). This probe consists of a mixture of two 
FISH DNA probes. The first probe is labelled in spectrum orange and flanks  the 
5‘ side of the EWSR1 gene and extends  inward to intron 4. The second probe is 
labelled in spectrum green and flanks the 3‘ side of the EWSR1 gene. There is 
a 7 kb between the two probes. The known breakpoints  within the EWSR1 gene 
are restricted to introns 7 through 10. FISH was performed according to the 
manufacturer‘s instructions. Cells lacking a t(22q12) rearrangement are 
expected to show two intact copies of EWSR1. Abnormal cells with t(22q12) 
show one fusion, one green and one orange signal pattern. For each sample, 
20 tumor cells were reviewed for the presence of fused or split green and 
orange signals. We defined a positive result as > 20% of cells having split 
signals. 
2.5 Tissue Microarray (TMA) and Immunohistochemistry
The TMAs were assembled using a tissue-arraying instrument (Beecher 
Instruments, Silver Springs, MD). Hematoxylin and eosin (H&E) slides were 
reviewed, representative areas with ES tumor cells were marked on the slides 
and the corresponding areas on the tissue block were transferred into the 
recipients blocks, using a 1.5 mm diameter stylet. After construction, 3 µm 
sections were cut and afterwards dried on slides at 56°C over night. After 
drying, slides were placed into a Lab vison PT module and treated with Citrate 
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buffer (Thermo Scientific, pH 6,0) for dewaxing and epitope recovery for 35 min 
at 95°C. Only slides for pancytokeratin staining were exposed to xylol, a series 
of alcohol concentrations and washed in aqua dest. for dewaxing and 
additionally pretreated with Proteinase K (Dako). After dewaxing, S100 staining 
was performed without pretreatment. Afterwards, slides were incubated with 
primary antibodies for 25 min:
CD99 (1:500, clone 12E7, Dako),  FLI-1 poly (polyclonal antibody, 1:1000, 
SC-356, Santa Cruz), FLI-1 mono (monoclonal antibody, 1:1000, clone 
G146-222, BD Pharmingen), pancytokeratin (1:300, MNF-116, Dako), ETAA16 
(monoclonal antibody, AK16, 1:400, clone SN 58 1857.15.30, Alexis 
Switzerland), caspase 8 (polyclonal antibody, 1:50, SC7890, Santa Cruz), 
neuron-specific enolase (1:3000, BBS/NC/VI-H14, Dako), CD57 (monoclonal 
antibody, 1:300, clone TB01, Dako), neurofilaments (monoclonal antibody, 
1:5000, clone 2F11, Dako) and  S100 (1:5000, Z 0311, Dako). This step was 
followed by incubation with Dako REAL Link, Biotinylated secondary antibodies 
(20 min), incubation with Dako REAL Streptavidin Alkaline Phosphatase 
(20 min) and visualisation by RED chromogen (2 x 8 min) using the Dako 
REAL Detection System, Alkaline Phosphatase/RED, Rabbit/Mouse (this Kit is 
based on the labeled streptavidin-biotin method). Primary antibodies were 
diluted in Dako Real antibody diluent. All staining-steps were performed using a 
Dako autostaining system. 
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3 Results
3.1 Patient data
Twenty-seven patients were male (67.5%) and 13 female (32.5%). Five of 40 
patients had metastases or presented with multifocal disease at diagnosis  (time 
from diagnosis until detection of metastases or multifocal disease within ≤ 3 
months), 35 patients developed metastases or relapses at least 3 months after 
initial diagnosis  (median time from diagnosis until first metastasis: osseous 
metastases (n = 12): 28.3 mths., pulmonary metastases (n = 16): 35.1 mths., 
local relapse (n = 3): 21.7 mths.). Nineteen patients died of disease (median 
time from diagnosis  until death for patients harbouring: pulmonary metastases 
(n = 7): 4.18 yrs., osseous metastases (n = 7): 2.60 yrs., local relapse (n = 2):
1.71 yrs.). Survival data of 5 patients were not available. Two primary tumor 
samples were not available. Hence, temporally differing metastases were 
researched. Seven patients presented 2 contemporaneous first metastases 
(multifocal) while 9 patients developed secondary metastases. 
3.2 Molecular pathology
To analyse whether metastases of ES might in some cases actually represent 
different tumors, we analysed the EWSR1 translocations of primary tumors and 
the corresponding metastases of 39 patients  by RT-PCR for EWSR1/FLI-1 and 
EWSR1/ERG fusion transcripts. RNA was extracted from 36 primary, 46 first 
and 9 secondary metastatic FFPE (n = 71) or FT (n = 20) tumor samples. RT-
PCR for a GAPDH-fragment was used to evaluate whether the samples 
contained suitable RNA for further analysis, and from 80 samples (87.9%) a 
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GAPDH-fragment could be amplified. All 11 GAPDH negative samples (12.1%) 
were FFPE samples. As GAPDH negative samples were not further analysed, 
32 matched samples (24 x primary tumor / first metastasis; 5 x primary tumor / 
first metastasis / secondary metastasis; 3 x first metastasis / secondary 
metastasis) remained for analysis of EWSR1 translocations  by RT-PCR using 
the primers listed in Table 2. In 7 cases no amplificates were detected by RT-
PCR in 2 independent RT-PCR attempts. Four of these samples were available 
and additionally analysed by FISH with break-apart probes  for EWSR1. Two of 
these samples had a break in EWSR1 while 2 samples were not evaluable.
Thus, 27 matched samples (19 x primary tumor / first metastasis; 1 x primary 
tumor / secondary metastasis; 4 x primary tumor / first metastasis / secondary 
metastasis; 3 x first metastasis / secondary metastasis) remained for 
comparison of ES specific fusion transcripts and were sequenced. In all but one 
cases, one fusion transcript was obtained per sample.
The sample taken from the primary tumor site of patient no. 14 harboured two 
different fusion transcripts [1 x t(11;22) EWSR1 7/FLI-1 6 and 1 x t(11;22) 
EWSR1 7/FLI-1 7)]. FISH of this sample revealed that only one t(22q12) 
rearrangement per cell was present. Thus, the two different EWSR1/FLI-1 
fusion transcripts are most likely due to differential splicing and not to the 
presence of 2 different translocations. 
Comparison of the matched samples revealed that all matched pairs carried the 
same translocation types. Table 3 shows the frequency of the obtained 
translocation variants revealed by molecular-pathological analysis. 
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Translocation type Totaln = 74
t(11;22) EWSR1 7/FLI-1 6 45 (60.8%)
t(11;22) EWSR1 7/FLI-1 5 17 (23%)
t(11;22) EWSR1 10 /FLI-1 5 4 (5.4%)
t(11;22) EWSR1 10/FLI-1 8 2 (2.7%)
t(11;22) EWSR1 10/FLI-1 6 2 (2.7%)
t(11;22) EWSR1 7/FLI-1 8 1 (1.4%)
t(11;22) with unknown exon breakpoints 3 (4.1%)
Table 3: Frequency of the obtained translocation types.
3.3 Immunohistochemistry
Fifty-four FFPE specimens taken from 34 of all 40 patients were available for 
TMA production. The markers listed in Table 4 were previously described in 
several studies as possible diagnostic tools for ES. The yet published reference 
data in this Table (second column) give an overview of the normal distribution of 
these markers in ES. Therefore, immunohistochemical staining of the 
assembled TMAs were performed in order to evaluate whether corresponding 
primary and metastatic tumor samples  differ in expression of these markers. We 
scored the results as (+) = positive or (-) = negative. CD99, FLI-1 poly and Ak16 
expression in ES tumor cells is shown in Figure 1. In 18 cases, we had the 
possibility to assemble several tumor samples from each individual patient, so 
that we were able to observe a chronological sequence of immunohistochemical 
and PAS staining (14 x primary tumor / first metastasis; 2 x primary tumor / first 
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metastasis / secondary metastasis; 2 x first metastasis / secondary metastasis). 
The concordance between the primary tumor site and all of its corresponding 
metastases or between first and secondary metastases is shown in Table 4. In 
case of patient no. 1 and no. 13 immunohistochemical staining for AK16 was 
constantly detectable while CD99 and FLI-1 poly differed in marker expression 
(Table 5; FLI-1 poly was  also negative in a FFPE sample of patient no. 34. 
Here, only a few tumor cells  were seen, CD99 and AK16 were weakly positive 
in a few of those cells).
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 A
 B
15
 C
Figure 1: CD99, FLI-1 poly and AK16 marker expression. Exemplarily, the 
tumor cells express CD99 (membranous pattern) (A), FLI-1 poly (nuclear 
pattern) (B) and AK16 (membranous pattern) (C) (original magnification, x100 
for A, B and C).
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Antibody Reference Primary tumor site 1. metastasis 2. metastasis Total Concordance
CD99 93% - 100% [16, 17, 24]
20 / 20
(100%)
25 / 27
(92.6%)
5 / 6
(83.3%)
94.3%
(50 / 53)
17 / 18
(94.4%)
panCK 20 - 25 %[11, 13]
4 / 21
(19%)
7 / 27
(26%)
1 / 6
(16.7%)
22.2%
(12 / 54)
15 / 18
(83.3%)
NSE 47.5% [19]
10 / 21
(47.6%)
15 / 26
(57.7%)
2 / 6
(33.3%)
50.9%
(27 / 53)
9 / 17
(52.9%)
S100 44% [17]
5 / 21
(23.8%)
10 / 27
(37%)
3 / 6
(50%)
33.3%
(18 / 54)
10 / 18
(55.6%)
NF 12.5% [4]
5 / 21
(23.8%)
7 / 26
(26.9%)
3 / 6
(50%)
28.3%
(15 / 53)
10 / 17
(58.8%)
FLI-1 poly 71 - 81% [12, 16]
21 / 21
(100%)
25 / 27
(92.6%)
5 / 6
(83.3%)
94.4%
(51 / 54)
15 / 18
(83.3%)
FLI-1 
mono
97 - 100 % 
[16, 20]
18 / 21
(85.7%)
22 / 27
(81.5%)
4 / 6
(66.7%)
81.5%
(44 / 54)
12 / 18
(66.6%)
AK 16 not available 21 / 21(100%)
27 / 27
(100%)
6 / 6
(100%)
100 %
(54 / 54)
18 / 18
(100%)
Caspase 8 92.6% [7]
20 / 21
(95.2%)
22 / 27
(81.5%)
5 / 6
(83.3%)
87%
(47 / 54)
13 / 18
(72.2%)
CD57 0% - 25% [4, 17]
7 / 21
(33.3%)
12 / 27
(44.4%)
4 / 6
(66.7%)
42.6%
(23 / 54)
8 / 18
(44.4%)
PAS 84 % [23]
20 / 21
(95.2%)
27 / 27
(100%)
6 / 6
(100%)
98.1%
(53 / 54)
17 / 18
(94.4%)
Table 4: Staining data for immunohistochemical markers used in this  study and 
PAS staining. Concordance includes all available samples of each patient. 
PanCK = pancytokeratin, FLI-1 poly / mono = polyclonal / monoclonal antibody. 
PAS = Periodic acid-schiff reaction.
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Patient no.: Primary tumor site 
CD99 FLI-1 poly AK16 Fusion transcript FISH t(22q12)
1 N/A N/A N/A t(11;22) 7/6 N/A
13 + + + t(11;22) 7/6 +
1. metastasis
CD99 FLI-1 poly AK16 Fusion transcript FISH t(22q12)
1 - + + - +
13 - - + - N/E
2. metastasis
CD99 FLI-1 poly AK16 Fusion transcript FISH t(22q12)
1 - - + N/E N/E
13 N/A N/A N/A N/A N/A
Table 5: Data of immunohistochemical staining, RT-PCR and FISH of patients 
no. 1 and no. 13 (+ = positive, - = negative; N/A = not available; N/E = not 
evaluable).
18
4 Discussion
The diagnosis  of ES is based on molecular-pathological techniques and 
immunohistochemical examination of tumor samples. We once found 2 
separate ES with distinct EWSR1 translocations in one patient and this 
disposed us to analyse primary tumors and corresponding metastases for 
differing translocation types. [2] We also analysed whether immuno-
histochemical marker expression varies during the course of disease. 
Thirty-nine patients were analysed for ES specific fusion transcripts in primary 
and metastatic tumor samples. All thereby received 27 matched tumor samples 
carried the same fusion transcripts. We additionally analysed 4 GAPDH positive 
FFPE samples lacking ES specific fusion transcripts by FISH. Two samples 
showed a t(22q12) rearrangement, while 2 samples were not evaluable. This 
indicates that FISH can improve and supplement the diagnostic specificity in 
ES. The appearance of 2 different ES in one patient with distinct EWS 
translocations is - according to this - a rare event. 
The immunohistochemical markers were previously described as important 
tools for diagnostic differentiation of ES. The best immunohistochemical staining 
data in this study were provided by the monoclonal antibody AK16. It was 
positive in all FFPE samples. AK16 recognises a surface antigen named 
ETAA16. Borowski et al. described that surface expression of ETAA16 seems to 
be restricted to ES cells – other small, blue, round cell tumors did not show an 
ETAA16 surface expression - and represents a highly selective and unique 
feature of ES cells. [3, 22] We are not aware of any published data of AK16 
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expression in FFPE samples. Therefore, further analyses should be made to 
confirm the sensitivity and especially the specificity of AK16. 
CD99, a cell-surface glycoprotein, is known to be a highly sensitive 
immunohistochemical marker for ES. [6, 24] In this study, it was negative in 3 
samples and we were not able to detect a ES specific fusion transcript by RT-
PCR in these tumor samples.
FLI-1 poly is a relatively sensitive and highly specific marker, while FLI-1 mono 
is  more sensitive but lacks specificity. [12, 20] Mhawech-Fauceglia proposed, 
that the most sensitive and specific test panel for the diagnosis  of ES / PNET is 
the combination of CD99 and FLI-1 poly. [16] Here, the FLI-1 poly antibody was 
– in comparison to the FLI-1 mono antibody - a highly sensitive 
immunohistochemical marker for ES. It was negative in 3 samples as well. Due 
to the fact that all CD99 and FLI-1 poly negative samples were taken from 
metastases, chemotherapeutical treatment might have affected the tumor cells. 
Both, CD99 and FLI-1 poly showed a high sensitivity and a comparable high 
concordance. Pancytokeratin was expressed in about 22% of samples and the 
concordance was comparatively high. This indicates  that pancytokeratin - if 
expressed - is a relatively stable marker. PAS was as well a stable and sensitive 
marker, but its  diagnostic benefit remains inferior. Caspase 8 was described as 
a sensitive marker for ES, but its expression showed intertumoral and 
intratumoral variation in intensity and heterogeneity of staining. [7] In our study, 
concordance data were inferior to those of AK16, CD99 and FLI-1 poly. Neuron-
specific enolase (NSE), S100, neurofilaments (NF) and CD57 also revealed 
inappropriate concordance data. NSE, S100, CD57 and NF can be helpful to 
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identify the neuronal differentiation of ES cells  [8], but the concordance data 
show that there is a high variation rate for each marker in between the primary 
tumor and its metastases. 
In concordance to the literature, our collective showed comparable clinical data. 
[5] Patients who developed pulmonary metastases showed a longer event-free-
survival than patients who developed osseous metastases. Furthermore, 
patients harbouring osseous metastases died earlier than patients that had 
pulmonary metastases. Ancillary, patients  with local relapses died earlier than 
patients with pulmonary or osseous metastases, indicating that local relapsing 
is intended by a worst prognosis. 
Taken together, metastases of ES usually carry the same translocations as the 
corresponding primary tumors and the presence of two different ES with distinct 
translocations in one patient is a rare event. FISH can improve and supplement 
the diagnostic specificity in ES. AK16, CD99 and FLI-1 poly should be used for 
immunohistochemical diagnostics  of ES if RT-PCR does not detect ES specific 
fusion transcripts in FFPE samples. AK16 seems to be the most sensitive 
marker in metastases. 
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